News | March 07, 2023
Sun Pharma completes acquisition of Concert Pharmaceuticals
The common stock of Concert will no longer be listed for trading on the Nasdaq Global Market
The common stock of Concert will no longer be listed for trading on the Nasdaq Global Market
Smart-performance, fully biodegradable biopolymer sourced from renewable raw materials
Julie is recognized as a highly engaging multi-cultural leader skilled in fluidly partnering with cross-functional teams to deliver results.
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
Ayurveda is one of the most advanced sciences of its times
At commercial scale, Bluestem's patent pending technologies will reduce carbon emission by an estimated 75% or more and be cost-competitive with petroleum based chemicals
The new sterile filling line meets cGMP aseptic filling regulatory requirements
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
The investment enhances Lonza’s capabilities and flexibility to support both clinical and commercial supply and will play a key role in meeting the growing market demand for bioconjugates
Subscribe To Our Newsletter & Stay Updated
